Six events that shaped antibody approvals in oncology by Suman Paul, Suman Paul, Shibin Zhou, Shibin Zhou

Subjects: Get full text

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial by Xiaoyang Hong, Yongjian Guo, Wenbo Shi, Kangshun Zhu, Licong Liang, Liteng Lin, Ye Chen, Jingwen Zhou, Jingjun Huang, Jiabai Huang, Yaozhu Wu, Wensou Huang, Mingyue Cai

Subjects: Get full text

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer by Satoshi Endo, Hisao Imai, Atsuto Mouri, Kasumi Tsukamoto, Kenji Masaki, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi, Junichi Nakagawa, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu

Subjects: Get full text

Late-onset and relapsed cytokine release syndrome after nivolumab treatment in a patient with head and neck squamous cell carcinoma: a case report by Tomoyuki Otsuka, Yoshiki Kojitani, Fumio Imamura, Junko Fukutake, Minako Nishio, Takashi Fujii, Toshihiro Kudo

Subjects: “…immune checkpoint inhibitor…”
Get full text

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA... by Ruichen Gao, Wenjun Liang, Jintao Chen, Mingxia Yang, Xiaowei Yu, Xiaohua Wang

Subjects: Get full text